Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Neurocrine Biosciences Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $12.46, while Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | NBIX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $96.95 | $185.50 |
52-Week Low | $11.55 | $123.10 |
Market Cap | — | $16.76B |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY (YieldMax MSTR Option Income Strategy ETF) trades at $12.82, up 2.31% today, but remains in a significant downtrend with a 67% decline year-to-date. The ETF faces structural challenges as high distribution yields mask substantial NAV erosion, with technical indicators showing neutral momentum amid bearish moving averages. Recent news highlights concerns about the fund returning investor capital as distributions while experiencing deep losses.
The outlook remains challenged by the ETF's structural limitations that cap upside potential while exposing investors to full downside risk. Investment opportunity exists only for sophisticated investors seeking high current income despite principal erosion, while risks include continued NAV decline, tax inefficiency, and dependence on MicroStrategy's volatile performance.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
